Rituximab biosimilar - Sunshine Guojian Pharmaceutical
Alternative Names: CMAB304; RetuxiraLatest Information Update: 14 Jan 2022
At a glance
- Originator Shanghai CP Guojian Pharmaceutical
- Developer Sunshine Guojian Pharmaceutical
- Class Anti-inflammatories; Antineoplastics; Antirheumatics; Eye disorder therapies; Immunotherapies; Monoclonal antibodies; Skin disorder therapies; Urologics; Vascular disorder therapies
- Mechanism of Action Antibody-dependent cell cytotoxicity; T lymphocyte stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Diffuse large B cell lymphoma
Most Recent Events
- 18 Dec 2019 No development reported - Phase-III for Diffuse large B cell lymphoma in China (IV)
- 20 Aug 2015 CMAB 304 is still in phase III development for Diffuse large B cell lymphoma in China (IV), company website mentions drug as soon to be launched product
- 30 Sep 2006 Phase-III clinical trials in Diffuse large B cell lymphoma in China (IV)